Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis

  |  Issue: December 2021  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021 Feb 18;384(7):599–604.
  2. FDA new drug application approval letter: Tavneos (avacopan). U.S. Food & Drug Administration. 2021 Oct 7.
  3. Tavneos (avacopan): Prescribing information. U.S. Food & Drug Administration. 2021 Oct.
  4. Hickman RJ. FDA’s Arthritis Advisory Committee narrowly endorses avacopan approval. www.the-rheumatologist.org. 2021 Aug 11.
  5. Arthritis Advisory Committee (AAC) meeting. U.S. Food & Drug Administration, Center for Drug Evaluation and Research. 2021 May 6.

Related Articles
    Sci Writers / shutterstock.com

    FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

    On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…

    Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

    A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis

    On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms…